Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2026 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer...
November 03, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
July 30, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
May 13, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American...